CincyTech Invests in Clarametyx to Advance Breakthrough Anti-Biofilm Therapies for Chronic Respiratory Disease

CincyTech is proud to announce its investment in Clarametyx Biosciences,a Columbus-based clinical-stage biotechnology company pioneeringimmune-enabling solutions to address bacterial biofilm-related chronicrespiratory diseases. This strategic investment will support Clarametyx’s continued development of its lead candidate, CMTX-101, a novel monoclonal antibody therapy targeting persistent infections in cystic fibrosis (CF)patients.

Founded in 2020 as a spinout from Nationwide Children’s Hospital, Clarametyx has rapidly advanced its anti-biofilm technology, completing successful Phase 1 trials and now progressing to a critical Phase[KH1] 2a trial of CMTX-101. The therapy is designed to disrupt biofilms—protective bacterial structures that drive chronic infections and antibiotic resistance—by targeting the DNABII protein essential for biofilm stability. This approach has the potential to transform treatment for CF and other chronic lung diseases, where biofilm-related infections remain a leading cause of morbidity and mortality.

“Our investment in Clarametyx represents a bold step toward solving one of the most persistent challenges in chronic infection management,” said Emma Off, President & CEO of CincyTech. “Their platform could change the standard of care for treatment and prevention of chronic biofilm infections in people living with cystic fibrosis, as well as potentially other serious lung conditions. We are proud to support a team with the scientific depth and vision to transform patient outcomes in such a meaningful way.”

Clarametyx’s lead program, CMTX-101, is being evaluated as an adjunctive therapy alongside inhaled antibiotics for people with CF suffering from chronic Pseudomonas aeruginosa infections. These infections are responsible for70% of premature deaths in CF due to their resistance to standard treatments. Early clinical results have shown that CMTX-101 is well-tolerated, with no serious adverse events reported, and the upcoming interim analysis from the Phase 2a trial will represent a significant value inflection point for the company.

“This valued support from CincyTech is more than an investment—it’s a partnership in helping us build a future where biofilm-driven infections no longer dictate the course of chronic lung disease,” said David Richards, CEO of Clarametyx. “With CincyTech’s deep experience in scaling early-stage biotech companies, we’re accelerating our ability to bring immune-enabling biofilm-targeting solutions to populations who need them most.”

The Series A extension funding, including CincyTech’s investment, will enable Clarametyx to continue development of its CMTX-101 therapeutic program and advance its promising CMTX-301 vaccine program targeting DNABII proteins.

For more information about Clarametyx and its innovative therapies, visit www.clarametyx.com.